Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-480P is a pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNA itself is a critical component of the spliceosome, the ribonucleoprotein complex responsible for pre-mRNA splicing in eukaryotes[3]. However, RNU6-480P, by definition, is a defective copy generated during evolution that does not produce a functional RNA molecule or protein. Pseudogenes like RNU6-480P often arise from gene duplication or retrotransposition events and typically accumulate disabling mutations that prevent their expression or function[2][5]. While some pseudogenes may have regulatory effects (for instance, acting as decoys for regulatory RNAs or RNA-binding proteins), there is no evidence that RNU6-480P is transcribed or has any such function. The canonical U6 snRNA is highly conserved and vital for the splicing process since it contributes to the catalytic core of the spliceosome. Due to its importance, there are numerous functional and pseudogene copies of U6 snRNA dispersed in the human genome[3]. Some human U6 pseudogenes retain structural features of the genuine U6 RNA but are mutated or otherwise non-functional[5]. The presence of pseudogenes like RNU6-480P reflects the evolutionary redundancy and the high copy number of U6-related sequences in the genome[3][5]. RNU6-480P has no established functional, therapeutic, or biomarker relevance, and its listing as a target or receptor is incorrect.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 480, pseudogene (RNU6-480P).